Eli Lilly的糖尿病和肥胖症药物Mounjaro(Mounjaro)现在由中国的国民保险承保,这增加了参保机会并挑战对手。 Mounjaro, Eli Lilly’s diabetes and obesity drug, is now covered by China’s national insurance, boosting access and challenging rivals.

Eli Lilly的糖尿病和肥胖症药物Mounjaro被添加到中国国家医疗保险报销名单中,使患者更容易获得且负担得起。 Mounjaro, Eli Lilly’s diabetes and obesity drug, has been added to China’s national medical insurance reimbursement list, making it more accessible and affordable for patients. 预计此举将增加其市场份额,并对Novo Nordisk和Roche等公司的竞争药物施加压力。 The move is expected to increase its market share and put pressure on competing drugs from companies like Novo Nordisk and Roche. 这一包容反映了中国日益重视扩大获得新陈代谢疾病创新治疗的机会。 The inclusion reflects China’s growing focus on expanding access to innovative treatments for metabolic diseases.